Zydus Lifesciences share price
You have to be logged in to add this to Watchlist.- ₹943.80(0.81%)November 7, 2025 15:52:56 PM IST
- NSE
- BSE
- Vol : 685.46K (NSE + BSE)Last 20 day avg : 939.03 K
Zydus Lifesciences is trading 0.81% upper at Rs 943.80 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 945.80 & 927.00. Zydus Lifesciences has given -3.60% in this year & -6.60% in the last 5 days. Zydus Lifesciences has TTM P/E ratio 20.08 as compared to the sector P/E of 23.79.There are 25 analysts who have initiated coverage on Zydus Lifesciences. There are 4 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 1,258.60 Crores in its last quarter.Listed peers of Zydus Lifesciences include Torrent Pharmaceuticals (0.58%), Dr Reddys Laboratories (0.02%), Zydus Lifesciences (0.81%).The Mutual Fund holding in Zydus Lifesciences was at 4.70% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Zydus Lifesciences was at 7.34% in 30 Sep 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Nov 07, 2025, 10:28 AM UTC
- BetaLow volatility0.56Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.13The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldHigher than industry1.17Annual dividends as a percentage of the stock price.
- P/BLower than historical values3.93The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values19.16Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation0.71The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in June quarter by 5.90% from Rs 6573.70 crore to Rs 6207.50 crore, year-on-year
- The company has grown its June quarter profit by 3.30% from Rs 1419.90 crore to Rs 1466.80 crore, year-on-year
The debt to equity of the company is higher than the industry median
- R1
- 1,001.05
- R2
- 1,021.35
- R3
- 1,055.35
- S1
- 946.75
- S2
- 912.75
- S3
- 892.45
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | Bullish | 3,575.00 | 0.58 | 1,20,517.52 | 58.52 | 14.87 | 0.96 | 17.63 |
| Dr Reddys Laboratories | Bearish | 1,205.30 | 0.02 | 1,00,591.29 | 19.00 | 3.2 | 0.62 | 2.34 |
| Zydus Lifesciences | Bearish | 943.80 | 0.81 | 94,968.37 | 21.43 | 4.2 | 1.10 | 0.13 |
| Lupin | Moderately Bullish | 1,970.85 | 0.76 | 90,020.98 | 27.27 | 5.19 | 0.41 | 11.80 |
| Abbott India | Bearish | 28,825.00 | -2.22 | 61,251.12 | 53.21 | 17.78 | 1.34 | 3.73 |
- Promoter(s) holds a high stake in the company at 74.99%
- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has increased by 0.21 percentage points from previous quarter
- Mutual Funds holding has decreased by 0.86 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-11-06 | Quarterly Results & Fund raising |
| 2025-08-12 | Quarterly Results |
| 2025-05-20 | Audited Results & Final Dividend |
| 2025-02-05 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE010B01027
- BSE Code532321
- NSE CodeZYDUSLIFE
Zydus Lifesciences is trading at 943.80 as on Fri Nov 07 2025 10:22:56. This is 0.81% upper as compared to its previous closing price of 936.25.
The market capitalization of Zydus Lifesciences is 94968.37 Cr as on Fri Nov 07 2025 10:22:56.
The average broker rating on Zydus Lifesciences is Hold. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 5 analysts have given a buy rating
- 11 analysts have given a hold rating
- 3 analysts have given a sell rating
- 2 analysts have given a strong sell rating
The 52 wk high for Zydus Lifesciences is 1059.00 whereas the 52 wk low is 797.05
Zydus Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 20.08
- Sector P/E: 23.79
- Dividend Yield: 1.17%
- D/E ratio: 0.38
Zydus Lifesciences reported a net profit of 4525.50 Cr in 2025.
The Mutual Fund Shareholding was 4.70% at the end of 30 Sep 2025.